Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilostazol/ginkgo-biloba - SK Chemicals

Next Previous
Search
Drug Profile

Cilostazol/ginkgo-biloba - SK Chemicals

Alternative Names: Cilostazol/ginkgo-biloba controlled release; Cilostazol/ginkgo-biloba immediate release; Renexin; SID 142

Latest Information Update: 14 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK Chemicals
  • Developer Asan Medical Center; SK Chemicals
  • Class Antiplatelets; Herbal medicines; Neuroprotectants; Small molecules; Tetrazoles; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • No development reported Arterial occlusive disorders; Ear disorders; Peripheral arterial disorders

Most Recent Events

  • 14 Oct 2021 No development reported - Phase-III for Ear disorders in South Korea (PO)
  • 14 Oct 2021 No development reported - Phase-III for Peripheral arterial disorders in South Korea (PO)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Arterial-occlusive-disorders in South Korea (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top